Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a postmarketing study to assess the overall performance and survivorship of the SIGMA HP® PARTIAL KNEE SYSTEM.
The purpose of this study is to collect more information about the Sigma HP® Partial Knee System made by DePuy International. The aim of this study is to measure how this particular type of knee replacement performs over a two year period.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sigma HP Partial Knee | Experimental | Partial knee replacement |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SIGMA HP PARTIAL KNEE | Device | SIGMA HP PARTIAL KNEE |
|
| Measure | Description | Time Frame |
|---|---|---|
| Survivorship (revision) | Kaplan Meier Survival analysis at 2 years (based on revision of the femoral or tibial components) | 2 years |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Types and Frequency of Adverse Events | Throughout the study | |
| Clinical outcome using the AKS score | 6 weeks, 6 months, 1 year and 2 years post-op | |
| Patient-reported outcome using the KOOS assessment |
Inclusion Criteria:
Male or female subjects, aged at least 21 years.
Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
Subjects, who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
Subject has non-inflammatory degenerative joint disease (NIDJD), including: osteoarthritis, posttraumatic arthritis, avascular necrosis and chondrocalcinosis.
Subject has a functional stable knee.
Subject, in the opinion of the Investigator, is suitable for either a single or bicompartmental knee replacement.
Subject meets the following selected radiographic parameters:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Orthopedic Institute IRCCS Galeazzi | Milan | Italy | ||||
| CDC, Citta di Palma |
| ID | Term |
|---|---|
| D010003 | Osteoarthritis |
| D006073 | Gout |
| D002805 | Chondrocalcinosis |
| ID | Term |
|---|---|
| D001168 | Arthritis |
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 weeks, 6 months, 1 year and 2 years post-op |
| Patient-reported outcome using the HAAS assessment | 6 weeks, 6 months, 1 year and 2 years post-op |
| Patient-reported outcome using the Kujala score | 6 weeks, 6 months, 1 year and 2 years post-op |
| Patient-reported outcome using the Oxford Knee Score | 6 weeks, 6 months, 1 year and 2 years post-op |
| Patient-reported outcome using the EQ-5D assessment | 6 weeks, 6 months, 1 year and 2 years post-op |
| Radiographic assessment | 6 weeks, 6 months, 1 year and 2 years post-op |
| Parma |
| Italy |
| Schulthess Klinik | Zurich | Switzerland |
| D000070657 |
| Crystal Arthropathies |
| D011686 | Purine-Pyrimidine Metabolism, Inborn Errors |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |